Ionis Pharmaceuticals Reports Positive Phase 3 HAE Study Results

Ionis Pharmaceuticals (IONS) has released an update.

Ionis Pharmaceuticals, Inc. announced successful topline results from the Phase 3 OASIS-HAE study for their drug donidalorsen, which targets hereditary angioedema (HAE). The press release detailing these findings was made public on January 22, 2024.

For further insights into IONS stock, check out TipRanks’ Stock Analysis page.